FDA Approval Activities for this Drug…

Exelon (rivastigmine tartrate) Capsules, 1.5 mg, 3 mg, 4.5 mg, & 6 mg., Novartis NDA 20-823/S3 01/05/01 05/09/03 Exelon (rivastigmine tartrate) Capsules, 1.5 mg, 3 mg, 4.5 mg, & 6 mg., Novartis NDA 20-823 4/21/00 8/16/01 4/24/00 10/11/01 Exelon Indication: is indicated for the treatment of mild to moderate dementia of the Alzheimer's type Exelon (rivastigmine tartrate) Solution, 2 mg/mL, Novartis NDA 21-025 4/21/00 4/24/00 4/24/00 4/11/02 Exelon Indication: is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Exelon (RIVASTIGMINE), Novartis Pharmaceuticals | Exelon (rivastigmine) capsules, Novartis Pharma, Labeling Revision | Exelon (rivastigmine) oral solution, Novartis Pharma, Labeling Revision

For the latest approval information, please locate this drug using this index.